CTOs on the Move

Editas Medicine

www.editasmedicine.com

 
What if you could repair broken genes? That is the question we ask ourselves every day at Editas Medicine. We`re a leading genome editing company focused on translating the power and promise of our proprietary genome editing systems into medicines to help transform the lives of people with genetically-defined diseases. Our goal is to discover, develop, manufacture, and commercialize transformative medicines for a range of serious diseases, including eye diseases, blood diseases, and cancer. We are a vibrant company full of hope, possibilities, and a belief that, working together as One Editas, we can truly revolutionize the development of medicines. ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Kevin Dushney
Vice President of Technology Profile
Vic Myer
Chief Technology Officer Profile

Funding

Editas Medicine raised $120M on 08/10/2015
Editas Medicine raised $215.6M on 06/23/2020
Editas Medicine raised $231M on 01/21/2021

Similar Companies

Nonlethal Technologies

Nonlethal Technologies, Inc is a Homer City, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AB Scientific

Welcome to AB Scientific. Suppliers of innovative products to Pharmaceutical, Clinical and Life Science laboratories in the UK and Ireland.

Fulcrum Therapeutics

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum`s proprietary product engine, FulcrumSeekâ„¢, identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The company has advanced losmapimod to Phase 2 clinical development for the treatment of facioscapulohumeral muscular dystrophy (FSHD). Fulcrum has also advanced FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and beta-thalassemia into Phase 1 clinical development.

AmCyte

AmCyte Inc. is a Santa Monica, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

OpGen

OpGen, Inc. is a leading innovator in rapid, accurate genomic and DNA analysis systems and services.